|
A modern method experimental for treating breast cancer using exemestane drug by hplc (high-performance liquid chromatography)
|
|
| Author:
|
VIPUL PRAJAPATI, DR.AKRUTI S KHODAKIYA
|
| Abstract:
|
Chemotherapy is safer than endocrine therapy with women who establish metastases to visceral breast cancer. The latest aromatase inhibitor studies have reported behavior in these patients; thus, anastrozole and exemestane have been systematically studied in postmenopausal patients in this setting. In a population of cancer patients receiving chemotherapy preceding research has indicated cognitive failure and/or cognitive effects, although the hormone treatment literature on cognitive is not that steady. As the value of estrogen for cognition accumulates information that cognitive cognition is gradually impaired by adjutant medicinal products for breast cancer (BC). New promising research has also shown a positive impact of ovarian suppression in Early patients with breast cancer. Interesting findings have appeared when exemestane was investigated in safe Breast cancer women at high risk as neoadjuvant and as a preventive agent. The common side effect profile of exemestane to other AIs like menopause symptoms, arthralgia, and bone loss normally works well. Finally, the option for endocrine therapy for all breast cancer phases can be seen as successful and well-tolerated. The cognitive capacity of BC patients in postmenopausal care was randomized to tamoxifen or exemestane after doxorubicin/ cyclophosphamide (EC) chemotherapy and their outcomes were contrasted with the non-cancer group.
|
| Keyword:
|
Breast cancer, HPLC, UPLC, Exemestane, DDQ.
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2021.13.01.587
|
| Download:
|
Request For Article
|
|
|